General Information |
Business: |
We are a clinical-stage biotechnology company applying our leadership position in the field of calcium dysregulation by targeting SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, which is a clinical syndrome characterized by poor heart function, resulting in inadequate blood flow to meet the body’s metabolic needs, as well as diabetes and neurodegenerative diseases. Our therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. MYDICAR, our most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with heart failure. SERCA2a was scientifically validated as a molecular target for heart failure in the 1990s and became a focus of internal discovery efforts for many large pharmaceutical companies. However, to date, no other company has been successful in targeting SERCA2a using traditional discovery methods. |
|
Industry: |
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
|
Employees: |
15 |
Founded: |
2000 |
|
Contact Information |
Address: |
12760 High Bluff Drive, Suite 240, San Diego, CA 92130 |
|
|
|
|
Financial Information |
|
Revenues: |
$ 0.0 mil (last 12 months) |
|
Net Income: |
$ -20.8 mil (last 12 months) |
|
IPO Profile |
|
|
|
|